Targeting of human and mouse T-lymphocytes by monoclonal antibody-HPMA copolymer-doxorubicin conjugates directed against different T-cell surface antigens

Journal of Controlled Release

Volumn 52, Issue 3, 1998, Pages 253-270

  Jelinkova M ^a   Strohalm, J ^b   Plocova D ^b   Subr V ^b   St'Astny M ^a   Ulbrich, K ^b   Rihova B ^a  

^a INSTITUTE OF MICROBIOLOGY   (Czech Republic)

^b INSTITUTE OF MACROMOLECULAR CHEMISTRY   (Czech Republic)

Author keywords

Affinity therapy; Antibody targeting; Anticancer drugs; Con A; Cytotoxicity; Doxorubicin; Mitogen stimulation; N (2 Hydroxypropyl)methacrylamide; Polymeric carrier; Targetable drugs

Indexed keywords

COPOLYMER; DOXORUBICIN DERIVATIVE; DRUG CARRIER; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CONJUGATE; CONTROLLED STUDY; CYTOTOXICITY; DRUG RELEASE; DRUG TARGETING; FEMALE; HELPER CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T CELL LYMPHOMA; T LYMPHOCYTE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, SURFACE; CONCANAVALIN A; DOXORUBICIN; DRUG CARRIERS; HUMANS; IODINE RADIOISOTOPES; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; POLYMETHACRYLIC ACIDS; RATS; T-LYMPHOCYTES;

EID: 0041461022     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(97)00210-1     Document Type: Article

References (60)

1. Jansen F.K., Blythman H.E., Cariére D., Casellas P., Gros O., Gros P., Laurent J.C., Paolucci F., Pau B., Poncelet P., Richer G., Vidal H., Voisin G.A. Immunotoxins: Hybrid molecules combining high specificity and potent cytotoxicity. Immunol. Rev. 62:1982;185-216.
2. Vitetta E.S., Uhr J.W. The potential use of immunotoxins in transplantation, cancer therapy, and immunoregulation. Transplantation. 37:1984;535-548.
3. Pastan I., Willingham M.C., FitzGerald D.G. Immunotoxins. Cell. 47:1986;641-652.
4. Press O.W., Eary J.F., Appelbaum F.R., Martin P.J., Badger Ch.C., Nelp W.B., Glenn S.G., Butchko G., Fisher D., Porter B., Matthews D.C., Fisher L.D., Bernstein I.D. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N. Engl. J. Med. 329:1993;1219-1224.
5. Press O.W., Howell-Clark J., Anderson S., Bernstein I. Retention of B-cell specific monoclonal antibodies by human lymphoma cells. Blood. 83:1994;1390-1397.
6. Gottstein C., Winkler U., Bohlen H., Diehl V., Engert A. Immunotoxins: Is there a clinical value? Ann. Oncol. 5:1994;S97-S103.
7. Manetti C., Le Doussal J.M., Rouvier E., Gruaz-Guyon A., Barbet J. Intracellular uptake and catabolism of anti-IgM antibodies and bispecific antibody-targeted hapten by B-lymphoma cells. Int. J. Cancer. 63:1995;250-256.
8. 2 antibody for the delivery of saporin in the treatment of lymphoma. J. Immunol. 141:1988;3662-3670.
9. Tazzari P.L., Zhang S., Chen Q., Sforzini S., Bolognesi A., Stirpe F., Xie H., Moretta A., Ferrini S. Targeting of saporin to CD25-positive normal and neoplastic lymphocytes by an anti-saporin/anti-CD25 bispecific monoclonal antibody: In vitro evaluation. Br. J. Cancer. 67:1993;1248-1253.
10. Kopeček J. Targetable polymeric anticancer drugs: Temporal control of drug activity. Ann. NY Acad. Sci. 618:1991;335-344.
11. Duncan R. Drug-polymer conjugates: Potential for improved chemotherapy. Anti-Cancer Drugs. 3:1992;175-210.
12. Říhová B., Jegorov A., Strohalm J., Mat'ha V., Rossmann P., Fornůsek L., Ulbrich K. Antibody-targeted cyclosporin A. J. Control. Release. 19:1992;25-40.
13. Seymour L.W., Ulbrich K., Steyger P.S., Brereton M., Šubr V., Strohalm J., Duncan R. Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. Br. J. Cancer. 70:1994;636-641.
14. 6 toward human hepatocarcinoma cell line (PLC/PRF/5) targeted with galactosamine and to mouse splenocytes targeted with anti-Thy1.2 antibodies. J. Control. Release. 25:1993;71-87.
15. Peterson C.M., Lu J.M., Sun Y., Peterson C.A., Shiah J-G., Straight R.C., Kopeček J. Combination chemotherapy and photodynamic therapy with N-(2-hydroxypropyl)methacrylamide copolymer-bound anticancer drug inhibit human ovarian carcinoma heterotransplanted in nude mice. Cancer Res. 56:1996;3980-3985.
16. Říhová B., Strohalm J., Plocová D., Šubr V., Šrogl J., Jelínková M., Šírová M., Ulbrich K. Cytotoxic and cytostatic effects of anti-Thy1.2 targeted doxorubicin and cyclosporin A. J. Control. Release. 40:1996;303-319.
17. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanisms of tumoritropic accumulation of proteins and the antitumor agent. Cancer Res. 6:1986;6387-6392.
18. Maeda H., Seymour L.W., Miyamoto Y. Conjugates of antitumor agents and polymers: Advances of macromolecular therapeutics in vivo. Bioconjugate Chem. 3:1992;351-362.
19. Říhová B., Kopečková P., Strohalm J., Rossmann P., Větvička V., Kopeček J. Antibody-directed affinity therapy applied to the immune system: In vivo effectiveness and limited toxicity of daunomycin conjugates of HPMA copolymers and targeting antibody. Clin. Immunol. Immunopathol. 46:1988;100-114.
20. Duncan R., Kopečková P., Strohalm J., Hume I.C., Lloyd J.B., Kopeček J. Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. 2. Evaluation of daunomycin conjugates in vivo against L1210 leukemia. Br. J. Cancer. 57:1988;147-156.
21. Putnam D., Kopeček J. Polymer conjugates with anticancer activity. Adv. Polym. Sci. 122:1995;55-123.
22. Říhová B. Antibody-targeted polymer-bound drugs. Folia Microbiol. 40:1995;367-384.
23. Št'astný M., Strohalm J., Ulbrich K., Říhová B. Abnormal differentiation of thymocytes induced by free cyclosporin A is avoided when CsA bound to HPMA copolymer carrier is used. Transplantation. 63:1997;1818-1827.
24. Mattes M.J., Major P.P., Goldenberg D.M., Dio A.S., Hutter R.V.P., Klein K.M. Patterns of antigen distribution in human carcinomas. Cancer Res. 50:1990;880s-884s.
25. Primus F.J., Kuhns W.J., Goldenberg D.M. Immunological heterogeneity of carcinoembryonic antigen: Immunohistochemical detection of carcinoembryonic antigen determinants in colonic tumors with monoclonal antibodies. Cancer Res. 43:1983;693-701.
26. Duke-Cohan J.S., Morimoto Ch., Schlossman S.F. Targeting of an activated T-cell subset using a bispecific antibody-toxin conjugate directed against CD4 and CD26. Blood. 82:1993;2224-2234.
27. Kopeček J., Rejmanová P., Chytrý V. Polymers containing enzymatically degradable bonds. 1. Chymotrypsin catalyzed hydrolysis of p-nitroanilides of phenylalanine and tyrosine attached to side-chains of copolymers of N-(2-hydroxypropyl)methacrylamide. Makromol. Chem. 182:1981;799-809.
28. Rejmanová P., Kopeček J., Pohl J., Baudyš M., Kostka V. Polymers containing enzymatically degradable bonds. 8. Degradation of side-chains of N-(2-hydroxypropyl)methacrylamide copolymers by bovine spleen cathepsin B. Makromol. Chem. 184:1983;2009-2020.
29. Šubr V., Strohalm J., Ulbrich K., Duncan R., Hume I.C. Polymers containing enzymatically degradable bonds. XII. Effect of spacer structure on the rate of release of daunomycin and adriamycin from poly[N-(2-hydroxypropyl)methacrylamide] copolymer drug carriers in vitro and antitumour activity measured in vivo. J. Control. Release. 18:1992;123-132.
30. Říhová B., Strohalm J., Plocová D., Ulbrich K. Selectivity of antibody-targeted anthracycline antibiotics on T-lymphocytes. J. Bioact. Compat. Polym. 5:1990;249-266.
31. Říhová B., Bilej M., Větvička V., Ulbrich K., Strohalm J., Kopeček J., Duncan R. Biocompatibility of N-(2-hydroxypropyl)methacrylamide copolymers containing adriamycin. Immunogenicity, and effect on haematopoietic stem cells in bone marrow in vivo and mouse splenocytes and human peripheral blood lymphocytes in vitro. Biomaterials. 10:1989;335-342.
32. Volfová I., Říhová B., Větvička V., Rossmann P., Ulbrich K. Biocompatibility of biopolymers. J. Bioact. Compat. Polym. 7:1992;175-190.
33. Říhová B., Kopeček J. Biological properties of targetable poly[N-(2-hydroxypropyl)methacrylamide]-antibody conjugates. J. Control. Release. 2:1985;289-310.
34. Julius M.H., Simpson E., Herzenberg L.A. A rapid method for the isolation of functional thymus derived murine lymphocytes. Eur. J. Immunol. 3:1973;645-649.
35. Dráber P., Zikán J., Vojtíšková M. Establishment and characterization of permanent murine hybridomas secreting monoclonal anti-Thy-1 antibodies. J. Immunogenet. 7:1980;455-474.
36. Press O.W., Farr A.G., Borroz K.I., Anderson S.K., Martin P.J. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res. 49:1989;4906-4912.
37. Pietersz G.A., Rowland A., Smyth M., McKenzie I.A.C. Chemoimmunoconjugates for the treatment of cancer. Adv. Immunol. 56:1994;301-383.
38. Cawley D.B., Herschman H.R., Gilliland D.G., Collier R.J. Epidermal growth factor-toxin A chain conjugates: EGF-ricin A is a potent toxin while EGF-diphteria fragment A is nontoxic. Cell. 22:1980;563-570.
39. Press O.W., Vitetta E., Farr A., Hansen J., Martin P. Evaluation of ricin A chain immunotoxins directed against human T cells. Cell Immunol. 102:1986;10-20.
40. Thorpe P.E., Blakey D.C., Brown A.N., Knowles P., Knyba R.E., Wallace P.M., Watson G.J., Wawrzynczak E.J. Comparison of two anti-Thy1.1-abrin A-chain immunotoxins prepared with different cross-linking agents: Antitumor effects, in vivo fate, and tumor cell mutants. J. Natl. Cancer Inst. 79:1987;1101-1112.
41. Press O.W., Martin J.P., Thorpe P.E., Vitetta E.S. Ricin A-chain containing immunotoxins directed against different epitopes on the CD2 molecule differ in their ability to kill normal and malignant T cells. J. Immunol. 141:1988;4410-4417.
42. Letvin N.L., Ritz J., Guida L.J., Yetz J.M., Lambert J.M., Reinherz E.L., Schlossman S.F. In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates. I. Effects of anti-T11 antibodies on the circulating T cell pool. Blood. 66:1985;961-966.
43. Matthay K.K., Abai A.M., Cobb S., Hong K., Papahadjopoulos D., Straubinger R.M. Role of ligand in antibody-directed endocytosis of liposomes by human T-leukemia cells. Cancer Res. 49:1989;4879-4886.
44. Geissler F., Anderson S.K., Venkatesan P., Press O. Intracellular catabolism of radiolabeled anti-μ antibodies by malignant B-cell. Cancer Res. 52:1992;2907-2915.
45. Ali S.A., Waren S.D., Richter K.Y., Badger C.C., Eary J.F., Press O.W., Krohn K.A., Bernstein I.D., Nelp W.B. Improving the tumor retention of radioiodinated antibody: Aryl carbohydrate adducts. Cancer Res. 50:1990;783s-788s.
46. 125I-daunomycin. J. Control. Release. 10:1989;37-49.
47. Duncan R., Seymour L.W., O'Harre K.B., Flanagan P.A., Wedge S., Hume I.C., Ulbrich K., Strohalm J., Šubr V., Spreafico F., Grandi M., Ripamonti M., Farao M., Suarato A. Preclinical evaluation of polymer-bound doxorubicin. J. Control. Release. 19:1992;331-346.
48. Keller G.A., Siegel M.W., Caras I.W. Endocytosis of glycophospholipid-anchored and transmembrane forms of CD4 by different endocytic pathways. EMBO J. 11:1992;863-869.
49. Sablinski T., Hancock W.W., Tilney N.L., Kupiec-Weglinski J.W. CD4 monoclonal antibodies in organ transplantation - A review of progress. Transplantation. 52:1991;579-584.
50. J. Kopeček, Biodegradation of polymers for biomedical use, in: H. Benoit, P. Rempp (Eds.), IUPAC Macromolecules, Pergamon Press, Oxford, 1982, pp. 305-320.
51. Kopeček J. The potential of water-soluble polymeric carriers in targeted and site-specific drug delivery. J. Control. Release. 11:1990;279-290.
52. Kopeček J., Duncan R. Targetable polymeric prodrugs. J. Control. Release. 6:1987;315-327.
53. V.T. DeVita, S. Hellman, S.A. Rosenberg, Principles of chemotherapy, in: V.T. DeVita, J.S. Hellman, S.A. Rosenberg (Eds.), Cancer: Principles and Practices of Oncology, J.B. Lippincott Co., Philadelphia, 1985, pp. 257-286.
54. Russell P.S., Colvin R.B., Cosimi A.B. Monoclonal antibodies for the diagnosis and treatment of transplant rejection. Annu. Rev. Med. 35:1984;63-75.
55. 2b monoclonal antibodies. Eur. J. Immunol. 20:1990;107-112.
56. Yousaf N., Howard J.C., Williams B.D. Targeting behavior of rat monoclonal IgG antibodies in vivo: Role of antibody isotype, specificity and the target cell antigen density. Eur. J. Immunol. 21:1991;943-950.
57. B. Říhová, Receptor-mediated targeted drug or toxin delivery, Adv. Drug Deliv. Rev. (in press).
58. G. Poste, R. Kirsch, T. Koestler, The challenge of liposome targeting in vivo, in: G. Gregoriadis (Ed.), Liposome Technology: Targeted Drug Delivery and Biological Interaction, Vol. 3, CRC Press, Boca Raton, FL, pp. 1-28.
59. Ulbrich K., Strohalm J., Šubr V., Plocová D., Duncan R., Říhová B. Polymeric conjugates of drugs and antibodies for site-specific drug delivery. Macromol. Symp. 103:1996;177-192.
60. Roy M., Aruffo A., Ledbetter J., Linsley P., Kehry M., Noelle R. Studies on the interdependence of gp39 and B7 expression and function during antigen-specific immune responses. Eur. J. Immunol. 25:1995;596-603.